European Neuropsychopharmacology最新文献

{"title":"Comment on “Comparative receptor pharmacology of antipsychotic drugs based on normalized binding affinity data and breadth of interaction”","authors":"Parth Aphale, Shashank Dokania, Himanshu Shekhar","doi":"10.1016/j.euroneuro.2025.09.002","DOIUrl":"10.1016/j.euroneuro.2025.09.002","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"100 ","pages":"Page 34"},"PeriodicalIF":6.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145118698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methodological gaps in treatment-resistant depression prediction","authors":"Hui Chen","doi":"10.1016/j.euroneuro.2025.08.578","DOIUrl":"10.1016/j.euroneuro.2025.08.578","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"100 ","pages":"Pages 24-25"},"PeriodicalIF":6.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144997510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Esketamine in bipolar depression: Are we overlooking critical subgroups and dosing details?","authors":"Yuqing You , Jinyan Guo , Weifeng Yao","doi":"10.1016/j.euroneuro.2025.09.007","DOIUrl":"10.1016/j.euroneuro.2025.09.007","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"100 ","pages":"Pages 31-32"},"PeriodicalIF":6.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145118702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antipsychotic polypharmacy in patients with schizophrenia between 1999 and 2024 in Denmark: Prevalence, time trends, and combinations","authors":"Mikkel Højlund ,&nbsp;Christopher Rohde ,&nbsp;Christiane Gasse ,&nbsp;Jesper Hallas ,&nbsp;Anders Fink-Jensen ,&nbsp;Christoph U. Correll ,&nbsp;Ole Köhler-Forsberg","doi":"10.1016/j.euroneuro.2025.08.580","DOIUrl":"10.1016/j.euroneuro.2025.08.580","url":null,"abstract":"<div><div>Antipsychotic polypharmacy (APP) remains common in the treatment of schizophrenia despite increased risk of adverse events and limited evidence of additional efficacy compared to antipsychotic monotherapy (APM). We conducted a nationwide, register-based cohort study to characterize APP among patients with schizophrenia in Denmark, 1997–2021. Patients were followed from year 3 after the schizophrenia diagnosis and onwards. APP was defined as treatment with ≥2 antipsychotics lasting ≥60 days. Of 29,696 patients with schizophrenia (55 % males; median age 29 years [interquartile range (IQR) = 22–41 years]; median follow-up 10.5 years [IQR 5.1–16.3]), 51 % of patients were exposed to APP at some point during follow-up. The one-year prevalence of APP decreased from 44 % in 2005 to 29 % in 2024. In 2024, 58 % of APP regimens involved quetiapine, and 52 % involved clozapine and/or partial dopamine receptor agonists. Median total dose of antipsychotics was significantly higher with APP than with APM (1.4 vs. 0.7 WHO-defined daily doses;<em>p</em> &lt; 0.001). In 2024, 43 % of APP included chlorprothixene or quetiapine (≤100mg/day). Use of APP was associated with male sex, more and longer hospitalizations, suicide attempts/self-harm, alcohol/substance use, use of antidepressants, mood stabilizers, hypnotics, or benzodiazepines (all <em>p</em> &lt; 0.001). Although the prevalence of APP in schizophrenia decreased from 2005 to 2024, one-third of patients with schizophrenia remained exposed to APP. Only half of APP included potentially evidence-based combinations with clozapine and/or partial dopamine-receptor agonists. APP was associated with higher total antipsychotic doses, but also with more severe schizophrenia illness. These findings can inform future studies to investigate the comparative efficacy and safety of specific APP combinations and potential opportunities for deprescribing APP.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"100 ","pages":"Pages 4-12"},"PeriodicalIF":6.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144907679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Commentaries on Article: “Differences in resting-state functional connectivity between depressed bipolar and major depressive disorder patients: A machine learning study”","authors":"Benedetta Vai ,&nbsp;Francesco Benedetti","doi":"10.1016/j.euroneuro.2025.09.004","DOIUrl":"10.1016/j.euroneuro.2025.09.004","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"100 ","pages":"Page 39"},"PeriodicalIF":6.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145118116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning and neuroimaging in mood disorders: A promising path forward","authors":"Mingyi Gu ,&nbsp;Qing Ren ,&nbsp;Xu Fan","doi":"10.1016/j.euroneuro.2025.08.582","DOIUrl":"10.1016/j.euroneuro.2025.08.582","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"100 ","pages":"Page 35"},"PeriodicalIF":6.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145118699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The potential of applying large-scale multi-omics data to unsupervised learning-based transdiagnostic clusters of individuals with severe mental disorders to identify pharmacodynamic targets","authors":"Mojtaba Oraki Kohshour ,&nbsp;Urs Heilbronner","doi":"10.1016/j.euroneuro.2025.09.006","DOIUrl":"10.1016/j.euroneuro.2025.09.006","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"100 ","pages":"Pages 26-28"},"PeriodicalIF":6.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145105751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis","authors":"Natalia E. Fares-Otero ,&nbsp;Monika Budde ,&nbsp;Jonathan Laatsch ,&nbsp;Mathias Harrer ,&nbsp;Teuntje Pelgrim ,&nbsp;Alexandra Philipsen ,&nbsp;Urs Heilbronner ,&nbsp;Eduard Vieta ,&nbsp;Roos van Westrhenen ,&nbsp;on behalf of the PSY-PGx Consortium","doi":"10.1016/j.euroneuro.2025.08.003","DOIUrl":"10.1016/j.euroneuro.2025.08.003","url":null,"abstract":"<div><div>We conducted a systematic review and meta-analysis to estimate the efficacy of pharmacogenetic (PGx)-guided antidepressant treatment compared to treatment as usual (TAU) on functional outcomes and quality of life (QoL) in people with anxiety and affective disorders. A PRISMA-compliant systematic search was performed up to 26/06/2025 to identify relevant prospective, randomised controlled trials (RCTs) in seven databases. The revised tool for Risk of Bias (RoB2) was used to assess the methodological qualities of the included studies (PROSPERO CRD42024518683). Of 2774 records, six studies were included comprising 2285 adult patients (PGx group: <em>n</em> = 1395, Mean age = 48.14 years; 55.68 % females; TAU group: <em>n</em> = 890, Mean age = 47.83 years, 58.22 % females). Three studies were included in random-effect meta-analyses. In these, PGx-guided antidepressant treatment significantly decreased functional disability, measured by the Sheehan Disability Scale/Inventory (SDS/I), compared to TAU (<em>k</em> = 3, Mean Difference = -2.85, <em>SE</em> = 1.32 [95 % CI: -5.44, -0.26], <em>p</em> = .031). The Hartung-Knapp adjustment of <em>p</em>-values yielded non-significant effects. Individually, one of these three studies reported a significant effect of PGx-guided treatment on overall SDS score, one on SDI Perceived Social Support partial score, and one no effect. Risk for bias was rated high for one study, with some concerns for the other five. Due to the small number of included trials, our ability to conduct analyses of heterogeneity, moderators and publication bias was limited. Nonetheless, our results suggest that PGx-guided antidepressant treatment may improve functioning in people with anxiety and affective disorders</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"100 ","pages":"Pages 13-23"},"PeriodicalIF":6.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144921188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to “Differences in resting-state functional connectivity between depressed bipolar and major depressive disorder patients: A machine learning study”","authors":"Yilin Xu,&nbsp;Yubin Yang","doi":"10.1016/j.euroneuro.2025.08.579","DOIUrl":"10.1016/j.euroneuro.2025.08.579","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"100 ","pages":"Pages 2-3"},"PeriodicalIF":6.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144902853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strategies for improving research on semaglutide in cocaine use disorder","authors":"Meng-Yuan Shen ,&nbsp;Han-Xiao Qu ,&nbsp;Jian-Nong Wu","doi":"10.1016/j.euroneuro.2025.08.450","DOIUrl":"10.1016/j.euroneuro.2025.08.450","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"99 ","pages":"Pages 54-55"},"PeriodicalIF":6.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144896307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}